Mohammad Alashqar Shares Fitusiran Review for Hemophilia A and B, With or Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Grateful to share that my review paper, “Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,” has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback.
This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.”
Read the full article here.
Article: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 10:27Sartaj Alam: CBC Analyzer – The Backbone of Modern Hematology Diagnostics
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC
-
May 30, 2026, 10:06Johann Morelle: Complement Inhibitors Are Reshaping Modern Nephrology
-
May 30, 2026, 09:49Flora Peyvandi: Exploring a Multidisciplinary Care Model for Hemophilia and Rare Diseases
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center